Neurobiological and molecular bases of methamphetamine-induce behavioral sensitization and spontaneous recurrence of methamphetamine psychosis, and its implication in schizophrenia

Current Psychiatry Reviews

Volumn 2, Issue 3, 2006, Pages 381-393

  Yui, Kunio ^a,b   Kajii, Yasushi ^c   Nishikawa, Toru ^d  

^a Kansai University of International Studies   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Behavioral sensitization; Flashbacks; Gene expression; Methamphetamine; Plasticity; Stress sensitization

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CANNABIS; CLOZAPINE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE 5; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; G PROTEIN COUPLED RECEPTOR; GLUTATHIONE TRANSFERASE P1; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; HALOPERIDOL; LYSERGIDE; MESCALINE; MESSENGER RNA; METHAMPHETAMINE; MITOGEN ACTIVATED PROTEIN KINASE; NERVE GROWTH FACTOR; NEUROTROPHIN 3; PHOSPHOPROTEIN DARPP 32; PROTEIN C FOS; PSILOCYBINE; PSYCHEDELIC AGENT; RAS PROTEIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR DELTA FOSB; TRANSCRIPTION FACTOR FOSB; UNINDEXED DRUG;

ANXIETY; CORPUS STRIATUM; DISEASE PREDISPOSITION; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; DRUG DEPENDENCE; EXPERIENCE; FEAR; GENE EXPRESSION; GENETIC RISK; HUMAN; IMMEDIATE EARLY GENE; LOW DRUG DOSE; NERVE CELL PLASTICITY; NORADRENERGIC SYSTEM; NUCLEUS ACCUMBENS; PARANOIA; PARANOID PSYCHOSIS; PATHOGENESIS; PREFRONTAL CORTEX; PREVALENCE; PRIORITY JOURNAL; RECEPTOR DENSITY; RECURRENCE RISK; RELAPSE; REVIEW; RISK FACTOR; RISK REDUCTION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; STRESS; THOUGHT DISORDER;

EID: 33747681597     PISSN: 15734005     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340006778018111     Document Type: Review

References (136)

1. Utena H. Behavioral aberrations in methamphetamine-intoxicated animals and chemical correlates in the brain. Prog Brain Res 1966; 21B: 192-207.
2. Ujike H, Sato M. Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis. Ann N Y Acad Sci 2004; 1025: 279-87.
3. Gelder M, Gath D, Mayou R. The abuse of alcohol and drug. Oxford Textbook of Psychiatry, 3rd ed. Oxford University Press, New York. 1993; 438-81.
4. Hall W, Darke S, Ross M, Wodak A. Patterns of drug use and risk-taking among injecting amphetamine and opioid drug users in Sydney. Australia Addiction 1993; 88: 509-16.
5. Sato M, Chen C-C, Akiyama K, Otsuki S. Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. Biol Psychiatry 1983; 18: 429-40.
6. Batki SL, Harris DS. Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesias. Am J Addict 2004; 13: 461-70.
7. Konuma K. Multiphasic clinical types of methamphetamine psychosis and its dependence. Psychiat Neurol Jap 1984; 86: 315-39 (In Japanese).
8. Sato M, Numachi Y, Hamamura T. Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. Schizophr Bull 1992; 18: 115-22.
9. Horowitz MJ. Flashbacks: recurrent intrusive images after the use of LSD. Am J Psychiatry 1969; 126: 147-51.
10. McGlothlin WH, Arnold DO. LSD revised: a ten year follow-up of medical LSD use. Arch Gen Psychiatry 1971; 24: 35-49.
11. Matefy RE, Kral RG. An initial investigation of the psychedelic drug flashback phenomena. J Consult Clin Psychol 1974; 6: 854-60.
12. Matefy RE, Hayes C, Hirsh J. Psychedelic drug flashbacks: subjective reports and biographical data. Addict Behav 1978; 3: 165-78.
13. Alercon RD. Flashback phenomena: clinical and diagnostic dilemmas. J Nerv Ment Dis 1982; 170: 217-23.
14. Yui K, Goto K, Ikemoto S, Ishiguro T. Methamphetamine psychosis: spontaneous recurrence of paranoid-hallucinatory states and monoamine neurotransmitter function. J Clin Psychopharmacol 1997; 17: 34-43.
15. Yui K, Goto K, Ikemoto S, et al. Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization. Mol Psychiatry 1999; 4: 512-23.
16. Yui K, Goto K, Ikemoto S, Ishiguro T. Stress induced spontaneous recurrence of methamphetamine psychosis: the relation between stressful experiences and sensitivity to stress. Drug Alcohol Depend 2000; 58: 67-75.
17. Yui K, Goto K, Ikemoto S, Ishiguro T. Increased sensitivity to stress in spontaneous recurrence of methamphetamine psychosis: noradrenergic hyperactivity with contribution from dopaminergic hyperactivity. J Clin Psychopharmacol 2000; 20: 165-74.
18. Yui K, Goto K, Ikemoto S, Ishiguro T. Susceptibility to subsequent episodes of spontaneous recurrence of methamphetamine psychosis. Drug Alcohol Depend 2000; 64: 133-42.
19. Janowsky DS, Risch C. Amphetamine psychosis and psychotic symptoms. Psychopharmacology 1979; 65: 73-7.
20. Segal DS, Janowsky DS. Psychostimulant-induced behavioral effects: possible models of schizophrenia. In: Lipton MA, DiMascio A, KIillam KF. Eds, Psychopharmacology: a generation of progress. Raven Press, New York. 1978; 1113-23.
21. Robinson TE, Becker JB. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res Rev 1986; 11: 157-98.
22. Irwin L, Ahiluwalia P, Anisman H. Sensitization of noradrenerine activity following acute and chronic footshock. Brain Res 1986; 379: 98-103.
23. Niesenbaum LK, Zigmond MJ, Sved AF, Abercrombie ED. Prior exposure to chronic stress results in enhanced synthesis and release of hippocampal norepinephrine in response to a novel stressor. J Neurosci 1991; 11: 1478-84.
24. Angrist B. Amphetamine psychosis: clinical variations of the symptoms. In: Segal, D.S. Ed, Amphetamine and its analogs: psychopharmacology, toxicology, and abuse. Academic Press, New York. 1994; 387-414.
25. Landau SI. International dictionary of medicine and biology. Vol. III. A Wiley Medical Publication, New York, 1986.
26. Wood PL, Altar CA. Dopamine release in vivo from nigrostriatal, mesolimbic, and mesocortical neurons utility of 3-methoxy-tyramine measurements. Pharmacol Rev 1988; 40: 163-7.
27. Cassen G, Roffman M, Kurc A, Orsulak PJ, Schildkrause JJ. Alterations in brain norepinephrine metabolism induced by environmental stimuli previously paired with inescapable shock. Science 1980; 209: 1138-9.
28. Kent AP, Stern GM, Webster RA. The effect of benserazide on the peripheral and central distribution and metabolism of lovodopa after acute and chronic administration in the rat. Br J Pharmacol 1990; 100: 743-8.
29. Bremner JD, Krystal JH, Southwick SM, Charney DS. Functional neuroanatomical correlates of the effects of stress on memory. J Traumatic Stress 1995; 8: 527-53.
30. Southwick SM, Krystal JH, Morgan A, et al. bnormal noradrenergic function in posttraumatic stress disorders. Arch Gen Psychiatry 1993; 50: 266-74.
31. Cahill L, Prins B, Weber M, McGaugh JL. Beta-Adrenergic activation and memory for emotional events. Nature 1994; 371: 702-4.
32. Post RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 1992; 149: 999-1010.
33. Hall KS, Dunner DL, Zeller G, Fieve PR. Bipolar illness: a prospective study of life events. Compr Psychiatry 1977; 18: 497-502.
34. Yehuda P, Resnick H, Kahana B, Giller EL. Long-lasting hormonal alterations to extreme stress in humans: normative or maladaptive? Psychosom Med 1993; 55: 287-97.
35. Anisman H, Zacharko RM. Behavioral and neurochemical consequences associated with stressors. Ann NY Acad Sci 1995; 771: 205-25.
36. Carlson GA, Bromet EJ, Sievers S. Phenomenology and outcome of subjects with early- and adult-onset psychotic mania. Am J Psychiatry 2000; 157: 213-9.
37. Stein MB, Tancer ME, Uhde TW. Major depression in patients with panic disorder: factors associated with course and recurrence. J Affect Dis 1990; 19: 287-96.
38. Lieberman JA, Kane JM, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology 1987; 91: 415-33.
39. Angrist B, Rotrosen J, Gershon S. Rsponses to apomorphine, amphetamine, and neuroleptics in schizophrenic patients. Psychopharmacology 1980; 67: 31-8.
40. Leff J. Stress reduction in the social environment of schizophrenic patients. Acta Psychiatr Scand 1994; 90 (Suppl 384): 133-9.
41. Norma RM, Malla AK. Stressful life events and schizophrenia. 1: a review of the research. Br J Psychiatry 1993; 162: 161-6.
42. Thurm I, Haefner H. Perceived vulnerability, relapse risk and coping in schizophrenia: an explorative study. Eur Arch Psychiatr Neurol Sci 1987; 237: 46-53.
43. Sheitman BB, Lee H, Strausas R, Lieberman JA. The evaluation and treatment of fast-episode psychosis. Schizophr Bull 1997; 23: 653-61.
44. Laruelle M. The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res Rev 2000; 31: 371-84.
45. Lieberman JA, Kinon BJ, Loebel AD. Dopaminergic mechanisms in idiopathic and drug-induced psychoses. Schizophr Bull 1990; 16: 97-110.
46. Lieberman JA, Sheitman BB, Kinon BJ. Neurochemical sensitization in the pathophysiology of schizophrenia: deficit and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology 1997; 17: 205-29.
47. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148: 1301-8.
48. van Kammen DP, Agren H, Yao JK, et al. Noraderenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia. Am J Psychiatry 1994; 151: 379-84.
49. van Kammen DP. The biochemical basis of relapse and drug response in schizophrenia: review and hypothesis. Psychol Med 1991; 21: 881-95.
50. Fava GA. Can long-term treatment with antidepressant drugs worse the course of depression? J Clin Psdychiat 2003; 64: 123-33.
51. Kobayashi H, Ide S, Hasegawa J, et al. Study of association between α-synuclein gene polymorphism and methamphetamine psychosis/ dependence. An N Y Acad Sci 2004; 1025: 325-34.
52. Ujike H, Harano M, Inada T, et al. Nine- or few repeat alles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis. Pharmacogenetics Journal 2003; 3: 242-7.
53. Gelernter J, Kranzler HR, Satel SL, Rao PA. Genetic association between dopamine transporter protein alles and cocaine-induced paranoia. Neuropsychopharmacology 1994; 11: 195-200.
54. Hashimoto K, Tsukada H, Nishiyama S, et al. Protective effects of N-acetyl-L-cysteine on the reduction of dopamine transporters in the striatum of monkeys treated with methamphetamine. Neuropsychopharmacology 2004; 29: 2018-23.
55. Hashimoto T, Hashimoto K, Matsuzawa D, et al. A functional glutathione S-transferase P1 gene polymorphismis associated with methamphetamine-induced psychosis I Japanese population. Am J Med Genet 2005; 135B: 5-9.
56. Ujike H.Genetic risk factor of methamphetamine psychosis: study by the Japanese Genetics Initiative for Drug Abuse (JGIDA). Jpn J Psychopharmacol 2004; 24: 299-302 (in Japanese).
57. Woody GE. Visual disturbances experienced by hallucinogenic drug abusers while driving. Am J Psychiatry 1970; 127: 683-6.
58. Halpern JH, Pope Jr HG. Hallucinogen persisting perception disorder: what do we know after 50 years? Drug Alcohol Depend 2003; 69: 109-19.
59. Ellis H. Mescal: a new artificial paradise. Contemp Rev 1998; 73, 130-41.
60. Wessen DR, Smith D. An analysis of psychedelic drug flashbacks. Am J Drug Alcohol Abuse 1976; 3: 425-38.
61. Lerner AG, Gelkopf M, Oyffe I, Finkel B, Katz S, Sigal M. LSD-induced hallucinogen persisting perception disorder treatment with clonidine: an open pilot study. Int Clin Psychopharmacol 2000; 45: 35-7.
62. Abraham HD, Aldridge AM, Gogia P. The psychopharmacology of hallucinations. Neuropsychopharmacology 1996; 14: 286-98.
63. Batzer W, Ditzler T, Brown C. LSD use and flashbacks in alcoholic patients. J Addict Dis 1998; 18: 57-63.
64. Stanton MD, Franklin RM. Drug flashbacks. II some additional findings. Int J Addict 1976; 11: 53-69.
65. Yanger J, Crumpton E, Rubenstein R. Flashbacks among soliders discharged as unfit who abused more than one drug. Am J Psychiatry 1983; 140: 857-61.
66. Holsten F. Flashbacks: a personal follow-up. Arch Psychiat Nervennkr 1976; 222: 293-304.
67. Stanton MD, Bardoni A. Drug flashbacks: reported frequency in a military population. Am J Psychiatry 1972; 129: 751-5.
68. Shick JF, Smith DE. Analysis of the LSD flashback. J Psychedelic Drugs 1970; 3: 13-9.
69. Abraham HD. Visual phenomenology of the LSD flashbacks. Arch Gen Psychiatry 1983; 40, 884-9.
70. Keeler MH, Reifler CB, Liptzin MD. Spontaneous recurrence of marijuana effect. Am J Psychiatry 1968; 125: 140-2.
71. Saidel DR, Babineau R. Single case study: prolonged LSD flashbacks conversion reactions. J Nerv Ment Dis 1976; 163: 352-5.
72. McGee R. Flashbacks and memory phenomena: a comment on "flashback phenomena-clinical and diagnostic dilemmas". J Nerv Ment Dis 1984; 172: 273-8.
73. Rosenthal SH. Persisting hallucinations following repeated administration of hallucinogenic drugs. Am J Psychiatry 1964; 121: 238-44.
74. Smart RG, Bateman K. Unfavorable reactions to LSD: a review and analysis of the available case reports. Can Med Assoc J 1967; 97: 1214-21.
75. Abraham WC, Williams JM. Properties and Mechanisms of LTP Maintenance. Neuroscientist 2003; 9: 463-74.
76. Pierce RC, Kalivas PW. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Brain Res Rev 1997; 25: 192-216.
77. Vanderschuren LJ, Kalivas PW. Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology (Berl) 2000; 151: 99-120.
78. Karler R, Finnegan KT, Calder LD. Blockade of behavioral sensitization to cocaine and amphetamine by inhibitors of protein synthesis. Brain Res 1993; 603: 19-24.
79. Sorg BA, Ulibarri C. Application of a protein synthesis inhibitor into the ventral tegmental area, but not the nucleus accumbens, prevents behavioral sensitization to cocaine. Synapse 1995; 20: 217-24.
80. Wang JQ, Tang Q, Parelkar NK, et al. Glutamate signaling to Ras-MAPK in striatal neurons: mechanisms for inducible gene expression and plasticity. Mol Neurobiol 2004; 29: 1-14.
81. Ohno M, Frankland PW, Chen AP, Costa RM, Silva AJ. Inducible, pharmacogenetic approaches to the study of learning and memory. Nat Neurosci 2001; 4: 1238-43.
82. Pierce RC, Pierce-Bancroft AF, Prasad BM. Neurotrophin-3 contributes to the initiation of behavioral sensitization to cocaine by activating the Ras/Mitogen-activated protein kinase signal transduction cascade. J Neurosci 1999; 19: 8685-95.
83. Cador M, Bjijou Y, Cailhol S, Stinus L. D-amphetamine-induced behavioral sensitization: implication of a glutamatergic medial prefrontal cortex-ventral tegmental area innervation. Neuroscience 1999; 94: 705-21.
84. Wolf ME. The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Prog Neurobiol 1998; 54: 679-720.
85. Tzschentke TM, Schmidt WJ. Glutamatergic mechanisms in addiction. Mol Psychiatry 2003; 8: 373-82.
86. Pawlak R, Magarinos AM, Melchor J, McEwen B, Strickland S. Tissue plasminogen activator in the amygdala is critical for stress-induced anxiety-like behavior. Nat Neurosci 2003; 6: 168-74.
87. Pang PT, Teng HK, Zaitsev E, et al. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science 2004; 306: 487-491
88. Fernandez-Monreal M, Lopez-Atalaya JP, Benchenane K, et al. Is tissue-type plasminogen activator a neuromodulator? Mol Cell Neurosci 2004; 25: 594-601.
89. Hashimoto T, Kajii Y, Nishikawa T. Psychotomimetic-induction of tissue plasminogen activator mRNA in corticostriatal neurons in rat brain. Eur J Neurosci 1998; 10: 3387-99.
90. Harlan RE, Garcia MM. Drugs of abuse and immediate-early genes in the forebrain. Mol Neurobiol 1998; 16: 221-67.
91. Meng ZH, Feldpaush DL, Merchant KM. Clozapine and haloperidol block the induction of behavioral sensitization to amphetamine and associated genomic responses in rats. Brain Res Mol Brain Res 1998; 61: 39-50.
92. Persico AM, Schindler CW, O'Hara BF, Brannock MT, Uhl GR. Brain transcription factor expression: effects of acute and chronic amphetamine and injection stress. Brain Res Mol Brain Res 1993; 20: 91-100.
93. Simpson JN, Wang JQ, McGinty JF. Repeated amphetamine administration induces a prolonged augmentation of phosphorylated cyclase response element-binding protein and Fos-related antigen immunoreactivity in rat striatum. Neuroscience 1995; 69: 441-57.
94. Turgeon SM, Blum JE, Auerbach EA. Behavioral sensitization to amphetamine is not accompanied by a decrease in the number of c-Fos containing cells in the striatum. Brain Res 1998; 782: 329-32.
95. Norman AB, Lu SY, Klug JM, Norgren RB. Sensitization of c-fos expression in rat striatum following multiple challenges with D-amphetamine. Brain Res 1993; 603: 125-8.
96. Curran EJ, Akil H, Watson SJ. Psychomotor stimulant- and opiate-induced c-fos mRNA expression patterns in the rat forebrain: comparisons between acute drug treatment and a drug challenge in sensitized animals. Neurochem Res 1996; 21: 1425-35.
97. Hamamura T, Ichimaru Y. Amphetamine sensitization augments amphetamine-induced Fos expression in the lateral habenula. Brain Res 1997; 767: 140-3.
98. Crombag HS, Jedynak JP, Redmond K, Robinson TE, Hope BT. Locomotor sensitization to cocaine is associated with increased Fos expression in the accumbens, but not in the caudate. Behav Brain Res 2002; 136: 455-62.
99. Hu XT, Koeltzow TE, Cooper DC, Robertson GS, White FJ, Vezina P. Repeated ventral tegmental area amphetamine administration alters dopamine D1 receptor signaling in the nucleus accumbens. Synapse 2002; 45: 159-70.
100. Ostrander MM, Badiani A, Day HE, et al. Environmental context and drug history modulate amphetamine induced c-fos mRNA expression in the basal ganglia, central extended amygdala, and associated limbic forebrain. Neuroscience 2003; 120: 551-71.
101. Hope BT, Nye HE, Kelz MB, et al. Induction of a long-lasting AP-1 complex composed of altered Fos-like proteins in brain by chronic cocaine and other chronic treatments. Neuron 1994; 13: 1235-44.
102. Chen J, Nye HE, Kelz MB, et al. Regulation of delta FosB and FosB-like proteins by electroconvulsive seizure and cocaine treatments. Mol Pharmacol 1995; 48: 880-9.
103. Bibb JA, Chen J, Taylor JR, et al. Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5. Nature 2001; 410: 376-80.
104. Chergui K, Svenningsson P, Greengard P. Cyclin-dependent kinase 5 regulates dopaminergic and glutamatergic transmission in the striatum. Proc Natl Acad Sci USA 2004; 101: 2191-6.
105. Cha XY, Pierce RC, Kalivas PW, Mackler SA. NAC-1, a rat brain mRNA, is increased in the nucleus accumbens three weeks eater chronic cocaine self-administration. J Neurosci 1997; 17: 6864-71.
106. Kalivas PW, Duffy P, Mackler SA. Interrupted expression of NAC-1 augments the behavioral responses to cocaine. Synapse 1999; 33: 153-9.
107. Mackler SA, Korutla L, Cha XY, et al. NAC-1 is a brain POZ/BTB protein that can prevent cocaineinduced sensitization in the rat. J Neurosci 2000; 20: 6210-7.
108. Mackler SA, Homan YX, Korutla L, Conti AC, Blendy JA. The mouse nac1 gene, encoding a cocaine-regulated Bric-a-brac Tramtrac Broad complex/ Pox virus and Zinc finger protein, is regulated by AP1. Neuroscience 2003; 121: 355-61.
109. Wang XB, Funada M, Imai Y, et al. rGbeta1: a psychostimulant-regulated gene essential for establishing cocaine sensitization. J Neurosci 1997; 17: 5993-6000.
110. Kitanaka N, Kitanaka J, Walther D, Wang XB, Uhl GR. Comparative inter-strain sequence analysis of the putative regulatory region of murine psychostimulant-regulated gene GNB1 (G protein beta 1 subunit gene). DNA Seq 2003; 14: 257-63.
111. Kosten TA, Miserendino MJ, Chi S, Nestler EJ. Fischer and Lewis rat strains show differential cocaine effects in conditioned place preference and behavioral sensitization but not in locomotor activity or conditioned taste aversion. J Pharmacol Exp Ther 1994; 269: 137-44.
112. Kabbaj M, Yoshida S, Numachi Y, Matsuoka H, Devine DP, Sato M. Methamphetamine differentially regulates hippocampal glucocorticoid and mineralocorticoid receptor mRNAs in Fischer and Lewis rats. Brain Res Mol Brain Res 2003; 117: 8-14.
113. Steckler T, Holsboer F. Conditioned activity to amphetamine in transgenic mice expressing an antisense RNA against the glucocorticoid receptor. Behav Neurosci 2001; 115: 207-19.
114. Ortiz J, DeCaprio JL, Kosten TA, Nestler EJ. Strain-selective effects of corticosterone on locomotor sensitization to cocaine and on levels of tyrosine hydroxylase and glucocorticoid receptor in the ventral tegmental area. Neuroscience 1995; 67: 383-97.
115. Harrigan MT, Campbell NF, Bourgeois S. Identification of a gene induced by glucocorticoids in murine T-cells: a potential G protein-coupled receptor. Mol Endocrinol 1991; 5: 1331-8.
116. Wang D, Herman JP, Pritchard LM, et al. Cloning, expression, and regulation of a glucocorticoid-induced receptor in rat brain: effect of repetitive amphetamine. J Neurosci 2001; 21: 9027-9035.
117. Fujiwara Y, Kazahaya Y, Nakashima M, Sato M, Otsuki S. Behavioral sensitization to methamphetamine in the rat: an ontogenic study. Psychopharmacol (Berl) 1987; 91: 316-9.
118. Kolta MG, Scalzo FM, Ali SF, Holson RR. Ontogeny of the enhanced behavioral response to amphetamine in amphetamine-pretreated rats. Psychopharmacol (Berl) 1990; 100: 377-82.
119. Nishikawa T, Umino A, Kashiwa A, Ooshima A, Nomura N, Takahashi K. Stimulant-induced behavioral sensitization and cerebral neurotransmission. In: Toru M Ed, Neurotransmitters in neuronal plasticity and psychiatric disorders. Tokyo, Excerpta Medica, Ltd. 1993; 53-62.
120. Kajii Y, Muraoka S, Hiraoka S, Fujiyama K, Umino A, Nishikawa T. A developmentally regulated and psychostimulant-inducible novel rat gene mrt1 encoding PDZ-PX proteins isolated in the neocortex. Mol Psychiatry 2003; 8: 434-44.
121. Fujiyama K, Kajii Y, Hiraoka S, Nishikawa T. Differential regulation by stimulants of neocortical expression of mrt1, arc, and homerla mRNA in the rats treated with repeated methamphetamine. Synapse 2003; 49: 143-9.
122. Wientjes FB, Segal AW. PX domain takes shape. Curr Opin Hematol 2003; 10: 2-7.
123. Ponting CP, Benjamin DR. A novel family of Ras-binding domains. Trends Biochim Sci 1996; 21: 422-5.
124. Licata SC, Pierce RC. The roles of calcium/calmodulin-dependent and Ras/ mitogen-activated protein kinases in the development of psychostimulant-induced behavioral sensitization. J Neurochem 2003; 85: 14-22.
125. Licata SC, Schmidt HD, Pierce RC. Suppressing calcium/ calmodulin-dependent protein kinase II activity in the ventral tegmental area enhances the acute behavioural response to cocaine but attenuates the initiation of cocaine-induced behavioural sensitization in rats. Eur J Neurosci 2004; 19: 405-14.
126. Jelen F, Oleksy A, Smietana K, Otlewski J. PDZ domains - common players in the cell signaling. Acta Biochim Pol 2003; 50: 985-1017.
127. Zhang M, Wang W. Organization of signaling complexes by PDZ-domain scaffold proteins. Acc Chem Res 2003; 36: 530-8.
128. Joubert L, Hanson B, Barthet G, Sebben M, Claeysen S, Hong W, Marin P, Dumuis A, Bockaert J. New sorting nexin (SNX27) and NHERF specifically interact with the 5-HT4(a) receptor splice variant: roles in receptor targeting. J Cell Sci 2004; 117: 5367-79.
129. Eglen RM, Wong EH, Dumuis A, Bockaert J. Central 5-HT4 receptors. Trends Pharmacol Sci 1995; 16: 391-8.
130. Nikonenko I, Jourdain P, Alberi S, Toni N, Muller D. Activity-induced changes of spine morphology. Hippocampus 2002; 12: 585-91.
131. Blanpied TA, Ehlers MD. Dendritic spine pathology: cause or consequence of neurological disorders? Biol Psychiatry 2004; 55: 1121-7.
132. Fiala JC, Spacek J, Harris KM. Microanatomy of dendritic spines: emerging principles of synaptic pathology in psychiatric and neurological disease. Brain Res Brain Res Rev 2002; 39: 29-54.
133. Uranova NA, Klintzova AJ, Istomin VV, Haselhorst U, Schenk H. The effects of amphetamine on synaptic plasticity in rat's medial prefrontal cortex. J Hirnforsch 1989; 30: 45-50.
134. Robinson TE, Kolb B. Alterations in the morphology of dendrites and dendritic spines in the nucleus accumbens and prefrontal cortex following repeated treatment with amphetamine or cocaine. Eur J Neurosci 1999; 11: 1598-604.
135. Norrholm SD, Bibb JA, Nestler EJ, Ouimet CC, Taylor JR, Greengard P. Cocaine-induced proliferation of dendritic spines in nucleus accumbens is dependent on the activity of cyclin-dependent kinase-5. Neuroscience 2003; 116: 19-22.
136. Meng Y, Zhang Y, Tregoubov V, Falls DL, Jia Z. Regulation of spine morphology and synaptic function by LIMK and the action cytoskeleton. Rev Neurosci 2003; 14: 233-40.